The role of biomarkers in clinical trials for Alzheimer disease.
Biomarkers are likely to be important in the study of Alzheimer disease (AD) for a variety of reasons. A clinical diagnosis of Alzheimer disease is inaccurate even among experienced investigators in about 10% to 15% of cases, and biomarkers might improve the accuracy of diagnosis. Importantly for the development of putative disease-modifying drugs for Alzheimer disease, biomarkers might also serve as indirect measures of disease severity. When used in this way, sample sizes of clinical trials might be reduced, and a change in biomarker could be considered supporting evidence of disease modification. This review summarizes a meeting of the Alzheimer's Association's Research Roundtable, during which existing and emerging biomarkers for AD were evaluated. Imaging biomarkers including volumetric magnetic resonance imaging and positron emission tomography assessing either glucose utilization or ligands binding to amyloid plaque are discussed. Additionally, biochemical biomarkers in blood or cerebrospinal fluid are assessed. Currently appropriate uses of biomarkers in the study of Alzheimer disease, and areas where additional work is needed, are discussed.
University of California San Diego, Department of Neurosciences, La Jolla, California, USA.
Leon J
LJ
Thal
Kejal
K
Kantarci
Eric M
EM
Reiman
William E
WE
Klunk
Michael W
MW
Weiner
Henrik
H
Zetterberg
Douglas
D
Galasko
Domenico
D
Praticò
Sue
S
Griffin
Dale
D
Schenk
Eric
E
Siemers
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000032:analysis*; D015415:Biomarkers / Q000032:analysis*; D001921:Brain / Q000473:pathology*; D018450:Disease Progression; D006801:Humans; D008279:Magnetic Resonance Imaging; D009419:Nerve Tissue Proteins / Q000032:analysis*; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D016875:tau Proteins
D016229:Amyloid beta-Peptides; D015415:Biomarkers; C054369:MAPT protein, human; D009419:Nerve Tissue Proteins; D016875:tau Proteins